Vertex Pharmaceuticals (VRTX) Return on Capital Employed (2010 - 2026)

Vertex Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 21.1% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 2503.0% year-over-year to 21.1% in Q1 2026; TTM through Mar 2026 was 21.1%, a 2503.0% increase from a year earlier, with the FY2025 full-year figure at 20.63%, up 2185.0% from the prior year.
• Return on Capital Employed advanced to 21.1% in Q1 2026 per VRTX's latest filing, from 19.51% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 33.0% in Q2 2022 and bottomed at 3.92% in Q1 2025.
• The 5-year median for Return on Capital Employed is 21.1% (2026), against an average of 17.94%.
• Across the five-year window, Return on Capital Employed sank 2620 bps in 2024 and soared 2503 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 29.33% in 2022, then slumped by 30 bps to 20.51% in 2023, then sank by 106 bps to 1.24% in 2024, then jumped by 1677 bps to 19.51% in 2025, then rose by 8 bps to 21.1% in 2026.
• Per Business Quant, the three latest VRTX Return on Capital Employed figures stand at 21.1% (Q1 2026), 19.51% (Q4 2025), and 19.99% (Q3 2025).